batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. Astra’s phase 3 is the encore to Merck’s $700m deal 14 August 2024 Argenx goes small with next Vyvgart trial 13 August 2024 Reality crashes in for Syros 13 August 2024 Lilly is down but not out of PI3K alpha inhibition 9 August 2024 Opinions split on SHP2 8 August 2024 Amgen’s Lumakras gets its colorectal date 7 August 2024 Pharmacosmos grants G1 a reprieve 7 August 2024 Merck and Daiichi team up again 6 August 2024 Load More